Lugital-SP Tablet is a combination analgesic and anti-inflammatory medication containing Aceclofenac (100mg), Paracetamol (325mg), and Serratiopeptidase (15mg). Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that effectively reduces inflammation and pain by inhibiting cyclooxygenase enzymes, thereby decreasing prostaglandin synthesis. Paracetamol provides analgesic and antipyretic effects through central inhibition of prostaglandin synthesis, complementing the anti-inflammatory action of Aceclofenac. Serratiopeptidase, a proteolytic enzyme, facilitates the breakdown of inflammatory byproducts and promotes the resolution of edema and tissue inflammation, enhancing overall therapeutic efficacy. This combination is indicated for the management of acute and chronic musculoskeletal pain, osteoarthritis, rheumatoid arthritis, postoperative inflammation, and soft tissue injuries. Lugital-SP Tablet offers rapid pain relief, reduction of swelling, and improvement in joint mobility. It should be used under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, active peptic ulcer, or severe hepatic or renal impairment. Common adverse effects may include gastrointestinal discomfort, nausea, or allergic reactions. Patients are advised to adhere to prescribed dosages and report any unusual symptoms to their healthcare provider promptly. Lugital-SP Tablet provides a synergistic approach to managing pain and inflammation, improving patient comfort and functional recovery.